Endocrine Abstracts

Bariatric surgery has had to change its name because as a ‘weight loss treatment’ it was far less successful than as a ‘health gain treatment’. The focus now is on metabolic surgery and no longer on just reducing kilograms but rather on improving organ function. The organs that appear to benefit most are those damaged by the combination of type 2 diabetes and excess adipocytes. At the heart of success of surgery is the significant gut adaptation which then ...

Appetite can be better defined as hunger and fullness. Both of these change significantly after bariatric surgery. Gut hormones such as Peptide YY (PYY) and Glucagon like peptide-1 (GLP-1) are gastrointestinal peptides implicated in appetite control and glycaemic homeostasis. In non-obese individuals these satiety gut hormones may be attenuated. Given that PYY and GLP-1 are secreted from enteroendocrine L cells in the intestine, it is not surprising that manipulation of the ga...

Introduction: There are few data on renal function following bariatric surgery. We evaluated the effect of Roux-en-Y gastric bypass (RYGB), adjustable gastric banding (AGB) and sleeve gastrectomy (SG) on renal function over a 5-year post-operative period. We also evaluate the effect of these procedures on remission of diabetes and hypertension.Methods: Analysis of a prospectively collected database at Lille University Hospital. Patients were assessed pre...

Background: The 3-year part of this trial investigated the effect of liraglutide 3.0 mg, as an adjunct to diet+exercise, in delaying onset of T2D (primary endpoint) in adults with prediabetes and obesity (BMI ≥30 kg/m2) or overweight (≥27 kg/m2) with comorbidities.Methods: Participants were randomised 2:1 to once-daily subcutaneous liraglutide 3.0 mg or placebo plus 500 kcal/day deficit diet and 150...